Published • loading... • Updated
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
The deal gives Telix greater control of isotope supply and could add up to $700 million in milestone payments tied to ITM-11 approvals.
- On Monday, Telix Pharmaceuticals announced it will acquire German isotope maker ITM Isotope Technologies Munich in a transaction valued at least $1.65 billion, creating a vertically integrated radiopharmaceutical leader.
- The merger combines Telix's therapeutic pipeline with ITM's commercial-scale radioisotope production, capitalizing on the nuclear medicine market forecast to reach $41 billion by 2034.
- Under the agreement, Telix shareholders will own approximately 76.3% of the combined group, while ITM shareholders will receive about $1.25 billion in Telix shares and own 23.7%.
- Additional milestone payments of up to $700 million depend on regulatory approvals and sales targets for ITM-11, a candidate for treating neuroendocrine tumors.
- Completion is expected by end of 2026, subject to regulatory approvals and an extraordinary general meeting for Telix shareholders scheduled for November 2026.
Insights by Ground AI
15 Articles
15 Articles
Australia’s Telix Pharma agrees to buy Germany’s ITM Isotope for about $1.65 billion - Regional Media News
Sept 21 (Reuters) - Australia's Telix Pharmaceuticals said on Monday it has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis. After adjustments, ITM shareholders are expected to receive about $1.25 billion in Telix shares [...]
Australia’s Telix Pharma agrees to buy Germany’s ITM Isotope for about $1.65 billion
Sept 21 (Reuters) - Australia's Telix Pharmaceuticals said on Monday it has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis. After adjustments, ITM shareholders are e...
Coverage Details
Total News Sources15
Leaning Left0Leaning Right3Center5Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
C 63%
R 37%
Factuality
To view factuality data please Upgrade to Premium
